10月15日，诺和诺德盘中上涨3.24%，报39.5美元/股，成交额1.34亿美元。
消息面上，GLP-1减重药市场长期空间预期持续受到关注，相关产品在成人及部分青少年人群中的适用进展，叠加下一代肥胖疗法向胰淀素等新机制延伸，支撑减重药主线热度。
此前市场预计该赛道到2030年最高年销售额可达1000亿美元；诺和诺德近期还围绕口服减重、长效递送及下一代肥胖管线持续布局，行业龙头礼来、阿斯利康等同日亦明显走强，带动制药板块情绪回暖。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.